CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner ...

RADIO AIRPLAY AUDIENCE IMPRESSIONS AS PROVIDED BY LUMINATE AND SALES DATA AS COMPILED BY LUMINATE Tyla Last week Weeks at no. 1 Weeks on chart T.L.Seethal, I.Lewis, C.M.Lindsay-Keay, A.Irosogie ...

The FT’s team of reporters, statisticians, illustrators, cartographers, designers, and developers work with colleagues across our newsrooms, using graphics and data to find, investigate and ...